Oxygen Absorber Packaging for Drug Stability

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Existing pharmaceutical packaging methods for oxygen-sensitive drugs are inefficient in reducing residual oxygen levels, leading to reduced shelf life and stability due to chemical complexity and limited nitrogen blanketing processes.

Innovation Solution

A pharmaceutical packaging system comprising a primary container with an oxygen-permeable component, a hermetically sealed secondary container with low oxygen permeability, and an oxygen absorber that removes oxygen from both containers, maintaining zero oxygen levels for extended periods.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If nitrogen blanketing is used during filling, then oxygen exposure is reduced, but residual oxygen levels remain at a few percent and shelf life is limited to six months

Engineering Contradiction:
Improvestability of oxygen-sensitive drugVSAvoidshelf life extension
Core Design Contradiction:
ReliabilityVSProductivity

Solution Approach 1:

The patent uses nitrogen blanketing during filling to create an inert atmosphere that prevents oxygen exposure, but combines this with oxygen absorbers placed in the primary packaging container to actively remove residual oxygen, achieving near-zero oxygen levels and extending shelf life beyond six months

Inventive Principle:
Principle #39Inert atmosphere (Inert environment)

Solution Approach 2:

The patent extracts oxygen from the packaging environment by incorporating oxygen absorbers that chemically bind and remove residual oxygen molecules, taking the harmful oxygen out of the system to achieve the desired near-zero oxygen levels for extended stability

Inventive Principle:
Principle #2Taking out (Extraction)

2Reliability

If chemical approaches (antioxidants, pH control) are used, then stability is enhanced, but formulation complexity increases and additional research is needed

Engineering Contradiction:
Improvestability of oxygen-sensitive drugVSAvoidformulation complexity
Core Design Contradiction:
ReliabilityVSDevice complexity

Solution Approach 1:

The patent introduces oxygen absorbers as intermediary components that physically and chemically remove oxygen from the packaging environment, providing stability protection without requiring complex chemical formulations or additional excipients in the drug solution itself

Inventive Principle:
Principle #24Intermediary (Mediator)

3Ease of manufacture

If standard nitrogen gassing process is used, then manufacturing is simplified, but residual oxygen levels remain high and shelf life is reduced

Engineering Contradiction:
Improvemanufacturing process simplicityVSAvoidshelf life of oxygen-sensitive product
Core Design Contradiction:
Ease of manufactureVSReliability

Solution Approach 1:

The patent performs preliminary nitrogen gassing during filling to establish an inert atmosphere, then adds oxygen absorbers that continue to remove residual oxygen over time, combining a simple manufacturing step with a passive ongoing oxygen removal mechanism to extend shelf life without complicating the manufacturing process

Inventive Principle:
Principle #10Preliminary action

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The system effectively maintains zero oxygen levels in both primary and secondary packaging for at least one year, significantly extending the shelf life and stability of oxygen-sensitive drugs.

Implementation Method 1

an oxygen absorber, wherein the oxygen absorber removes the oxygen present at the time of packaging assembly at a rate of up to 60%, up to 70%, up to 80%, up to 90%, or up to 100% per day in the secondary packaging

Methodology Applied
Scientific EffectAbsorption: Absorption (physical)

Implementation Method 2

a hermetically sealed secondary packaging which envelops the primary packaging container, wherein the secondary packaging has very low permeability to oxygen

Methodology Applied
Scientific EffectPermeation barrier: Permeation

Data Source

PatentEP3424547B1Packaging system for oxygen-sensitive drugs
Publication Date: 2026.02.11 FRESENIUS KABI AUSTRIA GMBH
  • EP3424547B1 patent drawingFigure 1a~1d
  • EP3424547B1 patent drawingFigure 2
  • EP3424547B1 patent drawingFigure 3

AI summary

Described herein are pharmaceutical packaging systems which prevent oxidative degradation of oxygen-sensitive drugs, such systems including a primary packaging container with an oxygen permeable component, a secondary packaging with very low permeability to oxygen and an oxygen absorber.